My junior kindergarten teacher asked me, 'What do you want to be when you grow up?' I said: 'A doctor!'
Growing up in Iran, Sayeh Lavasani, M.D., M.S., always knew she wanted to be a doctor, like so many members of her family (“Being a physician was natural to me,” she says.)
A top student, she excelled at Iran University of Medical Sciences in Tehran, then moved to Ontario, Canada, to continue her training at University of Toronto, Queen’s University in Kingston and McMaster University.
Dr. Lavasani specializes in treating HER2-positive breast cancer and has done extensive research in the field, publishing numerous papers and conducting multiple clinical trials.
Dr. Lavasani is excited about the many new treatment options available for HER2-positive breast cancer. Enabling her patients to defeat cancer and live healthy lives is something she finds especially rewarding. She feels honored to be part of the City of Hope team where “I can offer my patients the novel treatments and a chance to enroll in clinical trials which can help both patients and science.'
2009, Royal College of Physicians of Canada Certification Exam for Medical Oncology
2008, American Board of Internal Medicine
2008, Royal College of Physicians of Canada Certification Exam for Internal Medicine
M.D., Iran University of Medical Sciences, Tehran, Iran
M.Sc., Clinical Epidemiology and Health Care Research, University of Toronto, Toronto, Ontario, Canada
2009-2010, Breast Cancer, Sunnybrook Odette Cancer Center, University of Toronto, Ontario, Canada
2007-2009, Medical Oncology Postgraduate Program, Juravinski Cancer Centre, McMaster University Hamilton, Ontario, Canada
2004-2007, Internal Medicine Postgraduate Program, Kingston General Hospital, Queen’s University, Ontario, Canada
2003-2004, Ontario International Medical Graduate Program, Wightman Berris Academy, University of Toronto, Ontario, Canada
2018-present, Assistant Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA
2016-2018, Breast Medical Oncologist, Memorial Cancer Institute, Memorial Health Care System, Hollywood, FL
2011-2016, Assistant Professor of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI
Awards & Memberships
2016, Guardian of Excellence Award, Memorial Cancer Institute
2015, Best Teacher Award by hematology/oncology fellows at Wayne State University/Karmanos Cancer Institute
2010, ASCO Merit Award
2009-2010, Sunnybrook Odette Cancer Centre Fellowship Scholarship
2008, Appointed Fellow, Royal College of Physicians and Surgeons of Canada
2019-present, Member, Breast Cancer Risk Reduction Guidelines Committee, NCCN
2018-present, Member, American Society of Clinical Oncology (ASCO) Publishing Research Group
2018-present, Member, ASCO Technology Research Group
2018-present, Chair, Data and Safety Monitoring Board, Marker Therapeutics
2017-present, Volunteer, ASCO
2016-present, Member, Breast Committee, Alliance for Clinical Trials in Oncology
2016-present, Member, Community Oncology Committee, Alliance for Clinical Trials in Oncology
2013-present, Member, Survivors in Spirit Digital Community Advisory Board
2012-present, Member, Breast Cancer Committee, Southwest Oncology Group
2012-present, Member, Writing Group, Women's Health Initiatives (\VHI)
2007-present, Member, ASCO
2004-present, Member, Royal College of Physicians and Surgeons of Canada
2004-present, Member, Canadian/Ontario Medical Association
Lavasani S. Defining and Identifying Patients at High Risk for Breast Cancer. ASCO Daily News. March 3, 2021.
Mortimer J, Kruper L, Cianfrocca M, Lavasani S, Liu S, Tank-Patel N, Sedrak M, Smith W, Stewart D, Waisman J, Yeon C, Wang T, Yuan Y. Use of HER2-Directed Therapy in Metastatic Breast Cancer and How Community Physicians Collaborate to Improve Care. J Clin Med. 2020 June 24;9(6):1984.
Mahinbakht D, Lavasani S, Yu W, Samoa R, Ruel N, Mortimer J. Incidence of diabetes and prediabetes unmasked by dexamethasone in women undergoing (neo) adjuvant taxane therapy. J Clin Oncol. 2020;38:15_suppl, e12526-e12526.
Lavasani S. Surviving Burnout in Medical Oncology. ASCO Connection. Jan 2020 30.
Lavasani S. Leaving Lasting Impressions on Your Children. ASCO Connection. 2019 Sep 26.
ASCO Daily News, Clinical Corner: Duration of Adjuvant Chemotherapy for Early-Stage Breast Cancer.June 2018
Brasky T, Krok-Schoen J, Liu J, Chlebowski R, Freudenheim J, Lavasani S, Margolis K, Qi L, Reding K, Shields P, Simon M, Wactawski-Wende J, Wang A, Womack C, Manson J. Use of Calcium Channel Blockers and Breast Cancer Risk in the Women’s Health Initiative. Cancer Epidemiology, Biomarkers& Prevention 2017, 26(8):1345-1348
Liang X, Luo J, Chen Q, Margolis K, Hendryx M, Reeves K, Wassertheil-Smoller S, Weitlauf J, Danhauer S, Chlebowski R, Cann B, Qi L, Lane D, Lavasani S, Luo J. Effect of Depression before Breast Cancer Diagnosis on Mortality among Postmenopausal Women. Cancer 2017, 123(16):3107-3115
Breast Cancer Awareness. Memorial Physician Group monthly newsletter
Cancer Survivorship Planning. Memorial Cancer Institute Monthly Newspaper
Lavasani S, Mahinbakht A, Shields A. Chapter 2: Clinical Trials of Therapy Handbook for Clinical Trials of Imaging and Image-Guided Interventions.
Griffin T, Makambi K, Howard BV, Sarto GE, Lane DS, Lavasani S, Lessin L, Adams-Campbell LL. Validation of the National Cancer Institute’s Colorectal Cancer Risk Assessment Tool Among African-American and White Women in the Women’s Health Initiative Study. Publication pending
Lavasani S, Chlebowski RT, Prentice R, Kato I, Wactawski-Wende J, Johnson K, Young A, Hubbell FA, Mahinbakht A, Simon MS. Estrogen and Colorectal Cancer Incidence and Mortality. Cancer 2015 Sep 2;121(18):3261-71
Arun MP, Desai P, Lehman A, Kwan ML, Manson JE, Lavasani S, Wasswertheil-Smoller S, Sarto GE, LeBoff MS, Cauley J, Cote ML, Beebe-Dimmer J, Jay A, Chlebowski RT, Simon MS. Statins and Breast Cancer Stage and Mortality in the Women's Health Initiative Cohort. Cancer Causes and Control 2015, 26 (4):529-539
Zhao, S, Chlebowski, R, Anderson G, Kuller L, Manson J, Gass M, Patterson R, Rohan T, Lane D, Beresford S, Lavasani S, Rossouw J, Prentice R. Sex Hormone Associations with Breast Cancer Risk and the Mediation of Randomized Trial Postmenopausal Hormone Therapy Effects. Breast Cancer Research 2014, 16(2):R30
Zhou Y, Chlebowski R, LaMonte M, Bea J, Qi L, Wallace R, Lavasani S, Walsh B, Anderson G, Vitolins M, Sarto G, Irwin ML. BMI, Physical activity, and mortality in women diagnosed with ovarian cancer: results from the Women’s Health Initiative. Gynecology Oncology 2014, 133(1):4-10.
Mahinbakht A, Lavasani S, Guirguis,M. The Quality of Reporting Harm Data in Clinical Trials of Adjuvant Trastuzumab in Early Stage Breast Cancer Treatment. Therapeutic Innovation & Regulatory Science 2013; 48 (3):299-304
Verma S, Lavasani S, Mackey J, Pritchard K, Clemons M, Dent S, Latreille J, Lemieux J, Provencher L, Verma Sh, Chia S, Wang B, Rayson D. Optimizing the Management of HER2-Positive Early Breast Cancer: The Clinical Reality. Current Oncology 2010, 17(4):20-33
Lavasani SM, et al. Continuity Rate of IUD Use in Referrals to Shahre-Ray Health-Medical Centers Nabz Journal of Medicine 1993, 4(2):25-31
Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with 5 stars being the highest.
Provider listen carefully to you
Show respect for what you say
Spend enough time with you
Know important info medical history
Rate provider 0-10
Provider explain in way you understand
Recommend this provider office
Excellent - Verified patient
Excellent - Verified patient
Excellent - Verified patient
Very happy to/my care at COH. - Verified patient
Dr. Lavasani listened and explained everything I asked her. - Verified patient